National Prostate Cancer Awareness

Radioactive Prostate Cancer Drug Given NHS Go-Ahead

A radioactive prostate cancer drug has been recommended for routine NHS use following a decision by the National Institute for Health and Care Excellence (Nice).

Radium-223 dichloride, ailment marketed as Xofigo, no rx could be made available for treating prostate cancer patients as early as December.

The draft guidance on the drug – which homes in on tumours that have spread to the bones and attacks them with alpha radiation – is seen by charities an “important victory” for some patients.
It is hoped that Radium-223 can be used to help those who are too unwell to undertake chemotherapy.

Read Full Article Here >>

ADT Use in Blacks with Prostate Cancer Best Reserved for Those at High Risk

Androgen deprivation therapy (ADT) may be more risky a prostate cancer treatment approach in African-Americans than in others with this cancer, online possibly because this patient population has accompanying conditions that interact poorly with ADT and shorten survival, according to a recent study.

“The use of ADT in African-American men should be reserved for treating higher-risk prostate cancer, for which level-one evidence supports its use,” Dr. Anthony V. D’Amico, a professor of medicine at Harvard Medical School and chief of genitourinary radiation oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, wrote in the study, also reported in a press release.

Read Full Article Here >>